Technetium-99m sestamibi scintimammography: The influence of histopathological characteristics, lesion size and the presence of carcinoma in situ in the detection of breast carcinoma

European Journal of Nuclear Medicine

Volumn 26, Issue 11, 1999, Pages 1475-1481

  Howarth, Douglas ^b   Sillar, Robert ^a   Clark, David ^a   Lan, Linda ^b  

^a The Breast Centre Australia   (Australia)

^b NONE

Author keywords

Breast cancer; Carcinoma in situ; Scintimammography

Indexed keywords

METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; BREAST BIOPSY; BREAST CARCINOMA; CANCER SCINTISCANNING; CARCINOMA IN SITU; DIAGNOSTIC ACCURACY; FEMALE; HISTOPATHOLOGY; HUMAN; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; SCINTIMAMMOGRAPHY; TUMOR BIOPSY; TUMOR VOLUME;

BIOPSY, NEEDLE; BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; MAMMOGRAPHY; MIDDLE AGED; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TECHNETIUM TC 99M SESTAMIBI; ULTRASONOGRAPHY, MAMMARY;

EID: 0032747336     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002590050481     Document Type: Article

References (24)

1. Waxman A, Nagaraj N, Kovalevsky M, et al. Detection of primary breast malignancy with Tc-99m methoxybutylisonitrile (MIBI) in patients with non-palpable primary malignancies: the importance of lesion size. J Nucl Med 1995; 36: 194P-195P.
2. Sillar R, Howarth D, Clark D. The initial Australian experience of technetium-99m sestamibi scintimammography: a complementary test in the management of breast cancer. Aust NZ J Surg 1997; 67: 433-437.
3. Khalkali I, Cutrone JA, Mena IG, et al. Scintimammography: the complementary role of Tc-99m sestamibi prone breast imaging for the diagnosis of breast carcinoma. Radiology 1995; 196: 421-426.
4. Page DL, DuPont WD, Rogers LW, Landenberger M. Intraductal carcinoma of the breast: follow-up after biopsy only. Cancer 1982; 49: 751-758.
5. Evans AJ, Pinder SE, Snead DR, Wilson AR, Ellis IO, Elston CW. The detection of ductal carcinoma in situ at mammographic screening enables the diagnosis of small, grade 3 invasive tumours. Br J Cancer 1997; 75: 542-544.
6. Tabár L, Dean PB. Interventional procedures in the investigation of lesions of the breast. Radiol Clin North Am 1979; 17: 607-621.
7. Bevitt DJ, Milton ID, Piggot N, et al. New monoclonal antibodies to oestrogen and progesterone receptors effective for paraffin section immunohistochemistry. J Pathol 1997; 183: 228-232.
8. Elston CW. In: Page DL, Anderson TJ, eds. Diagnostic histopathology of the breast. Edinburgh: Churchill Livingstone; 1987: 300-311.
9. Armitage P, Berry G. Statistical methods in medical research, 3rd edn. Oxford: Blackwell Science; 1994: 522-528.
10. O'Brien PC, Shampo MA, Robertson JS. Statistics for nuclear medicine part 3: A. Comparing two proportions (the relative deviate test and chi-square equivalent). B. Counting data. J Nucl Med 1983; 24: 269-272.
11. Mekhmandarov S, Sandbank J, Cohen M, Lelcuk S, Lubin E. Technetium-99m MIBI scintimammography in palpable and non-palpable breast lesions. J Nucl Med 1998; 39: 86-91.
12. Waxman, A. The role of Tc-99m methoxyisobutylisonitrile in imaging breast cancer. Semin Nucl Med 1997; 1: 40-54.
13. Steinberg JL, Trudeau ME, Ryder DE, et al. Combined fine-needle aspiration, physical examination and mammography in the diagnosis of palpable breast masses: their outcome for women with primary breast cancer. Can J Surg 1996; 39: 302-311.
14. Howarth DM, Sillar R, Lan L, Clark D, Miles T. Scintimammography: an adjunctive test for patients with breast cancer. Med J Aust 1999; 170: 588-591.
15. Palmedo H, Biersack HJ, Lastoria S, et al. Scintimammography with technetium-99m methoxybutylisonitrile: results of a prospective European multicentre trial. Eur J Nucl Med 1998; 25: 375-385.
16. Khalkhali I, Cutrone I, Mena I, et al. The usefulness of scintimammography in patients with dense breast on mammogram. J Nucl Med 1995; 36: 52P.
17. Gupta P, Waxman A, Nguyen K, et al. Correlation of Tc-99m sestamibi uptake with histopathologic characteristics in patients with benign breast disease. J Nucl Med 1996; 5: 250P.
18. Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 1985; 312: 146-151.
19. Scopinaro F, Schillaci O, Scarpini M, et al. Technetium-99m sestamibi: an indicator of breast cancer invasiveness. Eur J Nucl Med 1994; 21: 984-987.
20. Bourgeois P. The use of technetium-99m sestamibi to indicate breast cancer invasiveness. Eur J Nucl Med 1995; 22: 581-582.
21. Palmedo H, Shombury A, Grunwald F, Bender H, Mallman P, Biersack H. Mammoscintigraphy with Tc99m MIBI: planar and SPECT imaging techniques in patients with suspicious breast nodules. J Nucl Med 1995; 36: 1758-1765.
22. 99mTc-MIBI scintimammography. Anticancer Res 1997; 17: 1631-1634.
23. Khalkhali I, Cutrone JA, Diggles L, Mishkin FM. The role of nuclear medicine imaging for the evaluation of patients with breast abnormalities. In: Freeman LM, ed. Nuclear medicine annual 1996. Philadelphia: Lippincott-Raven; 1996: 113-142.
24. R, Robidoux A, Lambert R, Turpin S, Laperrière J. Technetium-99m sestamibi prone scintimammography to detect primary breast cancer and axillary lymph node involvement. J Nucl Med 1995; 36: 1758-1765.